Hydrocortisone (Topical)

Introduction Overview

Generic Name

Brand Name

Ala-Cort, Ala-Scalpt, Anucort-HC, Anu-Med HC, Anusert HC, Anusol-HC, Aquanil HC, Caldecort Anti-Itch, Cetacort, CortaGel Extra Strength, Cortaid Intensive Therapy, Cortaid Maximum Strength, Cortaid Sensitive Skin Formula, Cortenema, Corticaine, Cortifoam, Cortizone for Kids, Cortizone, Cortizone External Anal Itch Relief, Cortizone Scalp Itch Formula, Dermacort, Dermarest, DriCort, DermiCort, Dermtex HC, Gynecort, Hemorrhoidal-HC, Hemril-HC, HydroSKIN, Hytone, LactiCare-HC, Lanacort, Locoid, Massengill Medicated Soft Cloth Towelette, Nupercainal Hydrocortisone Anti-Itch, Nutracort, Orabase HCA, Pandel, Penecort, Preparation H Hydrocortisone, Proctocort, Sarnol HC, Scalp-Aid, Scalpcort Maximum Strength, Texacort, Westcort

Dosage Form

Cream, Lotion, Ointment, Gel, Solution, Aerosol Foam, Suspension, Paste, Pledgets, Retention Enema, Suppository

Drug Class

Corticosteroids

Pharmacokinetics

Absorption:
Hydrocortisone topical formulations demonstrate variable percutaneous absorption, influenced by factors such as skin integrity, vehicle type, site of application, corticosteroid concentration, and occlusive dressing use. In intact skin, systemic absorption is minimal as most of the drug remains in the epidermal layers. However, absorption is significantly enhanced on thin-skinned areas such as the scrotum, axilla, eyelids, face, and scalp compared to the forearms, palms, and soles. Disruption of the stratum corneum due to inflammation, diseases like eczema or psoriasis, or loss of keratin layers further increases penetration. Occlusive dressings can markedly increase absorption, especially when maintained for prolonged durations (up to 96 hours), enhancing percutaneous delivery. For rectal administration, hydrocortisone enema achieves systemic absorption estimated between 30-90% in healthy subjects, with potentially higher absorption in inflamed mucosa.

Distribution:
Following percutaneous absorption, hydrocortisone is systemically distributed, but the extent of distribution after topical application is not well defined. Distribution into human milk has not been established. Due to minimal systemic levels with proper topical use, significant systemic exposure is typically avoided. When absorbed, hydrocortisone distributes in the extracellular fluid and is capable of penetrating various tissues, mimicking endogenous corticosteroid distribution.

Metabolism:
Absorbed hydrocortisone undergoes extensive hepatic metabolism, primarily by reduction and conjugation reactions to inactive metabolites. Phase I enzymes, including 11β-hydroxysteroid dehydrogenase, convert hydrocortisone to cortisone and other metabolites. These metabolic pathways facilitate rapid clearance and minimize systemic corticosteroid effects. The metabolic profile is consistent with endogenous cortisol processing.

Elimination:
Elimination of hydrocortisone and its metabolites occurs mainly via renal excretion, with a smaller fraction eliminated in the bile. The drug's half-life after topical administration is not well characterized due to negligible systemic concentrations under normal use. However, systemic absorption in large surface areas, occlusion, or mucosal application may alter pharmacokinetics, potentially increasing systemic corticosteroid exposure and downstream elimination dynamics.

Dosage Forms

Available Dosage Forms:
Hydrocortisone topical formulations are available in a broad array of dosage forms to accommodate diverse clinical indications and sites of application. These include:
- Creams: Concentrations of 0.5%, 1%, 2.5% with various brands incorporating adjunctive excipients such as aloe, parabens, propylene glycol.
- Lotions: 0.5%, 1%, 2%, 2.5% concentrations, often with adjunct preservatives and emollients.
- Ointments: 0.5%, 1%, 2.5% formulations providing occlusive properties ideal for dry, scaly lesions.
- Gels: 1% concentration primarily used for scalp and hairy areas offering non-greasy application.
- Solutions: 1% strength with alcohol-based vehicles suitable for hairy areas and scalp.
- Aerosol foams and suspensions: 10% concentration hydrocortisone acetate foams used rectally and topically.
- Pastes: 0.5% hydrocortisone acetate paste for oral mucosal lesions.
- Pledgets: 0.5%, medicated cloth towelettes saturated with solution.
- Rectal formulations: creams (1%), suspensions (100 mg/60 mL), retention enemas, suppositories (25 mg, 30 mg).
Dosages for Adults and Adolescents:
- Corticosteroid-responsive dermatoses: Topical application of cream, lotion, ointment, or solution sparingly 1 to 4 times daily.
- Aerosol foam for dermatoses: 2 to 4 times daily.
- Oral lesions: Paste applied 2-3 times daily after meals and bedtime.
- Ulcerative colitis: Rectal retention enema typically 100 mg nightly for 21 days; aerosol foam 90 mg once or twice daily; suppositories 25 mg twice daily for 2 weeks or as per severity.
- Anorectal conditions: Rectal creams or ointments applied externally; suppository dosing varies from 10 to 50 mg per day depending on condition.
Specific Patient Populations:
- Pediatric patients ≥2 years: Use minimal effective quantity, sparingly 1 to 4 times daily; nonprescription formulations should not be used under 2 years without clinician supervision.
- Use caution in patients with impaired skin barrier where absorption may increase systemic exposure.
- Occlusive dressings are reserved for severe or resistant dermatoses; potential to enhance absorption necessitates monitoring.
- Patients with anorectal inflammatory disorders may require rectally applied forms with adjusted dosing schedules.
- Use in pregnancy and lactation requires caution; systemic absorption generally low but risk-benefit evaluation recommended.

Mechanism Of Action

Hydrocortisone is a synthetic corticosteroid analogous to endogenous cortisol, produced by the adrenal cortex. Its primary mechanism in topical formulations involves binding to intracellular glucocorticoid receptors in target cells within the skin and mucous membranes. Upon receptor binding, hydrocortisone-receptor complexes translocate to the nucleus, modulating the transcription of glucocorticoid responsive genes, leading to altered synthesis of proteins that regulate inflammation and immune responses.

Biochemically, hydrocortisone induces the synthesis of lipocortins (also known as annexins), proteins that inhibit phospholipase A2. This inhibition decreases the release of arachidonic acid from membrane phospholipids, subsequently reducing the formation of potent proinflammatory mediators such as prostaglandins and leukotrienes. Additionally, hydrocortisone stabilizes lysosomal membranes in leukocytes, limiting the release of destructive enzymes and diminishing local tissue injury.

Hydrocortisone exerts vasoconstrictive effects through decreased capillary permeability and suppression of endothelial cell adhesion molecules, resulting in reduced edema and erythema. It also inhibits migration and activation of inflammatory cells like macrophages and neutrophils, diminishes histamine release, and counteracts kinin-mediated vascular responses. Furthermore, hydrocortisone downregulates fibroblast proliferation and collagen synthesis, mitigating fibrosis and scar tissue formation in chronic dermatoses.

Clinically, these combined actions contribute to relief of inflammatory and pruritic symptoms in corticosteroid-responsive dermatoses, infected dermatoses (when combined with anti-infective agents), oral mucosal inflammatory lesions, and anorectal inflammatory conditions. Compared to more potent topical corticosteroids, hydrocortisone offers milder anti-inflammatory effects with a lower risk of adverse systemic effects, making it suitable for delicate or pediatric skin applications, or when extended use is necessary under supervision.

Research supports that differences in vehicle composition and drug concentration significantly affect percutaneous absorption, bioavailability, and hence therapeutic efficacy. Hydrocortisone’s relatively low potency among topical corticosteroids is advantageous for minimizing adverse effects while providing effective symptom relief in mild to moderate inflammatory skin disorders.

Pharmacological Actions

Anti-inflammatory: reduces inflammation by inhibiting arachidonic acid cascade and inflammatory mediator synthesis.
Antipruritic: alleviates itching by stabilizing mast cells and reducing histamine release.
Vasoconstrictive: causes local constriction of blood vessels, decreasing erythema and edema.
Immunosuppressive: suppresses immune cell activation and cytokine production at the site of application.
Inhibits leukocyte migration and lysosomal enzyme release, preventing tissue damage.
Decreases fibroblast proliferation and collagen deposition, reducing scar formation.
Stabilizes lysosomal membranes in inflammatory cells, limiting release of degradative enzymes.
Reduces capillary permeability, mitigating plasma exudation and inflammatory swelling.
Suppresses kinin and complement-mediated inflammatory responses.
Exerts local corticosteroid receptor-mediated transcriptional effects impacting multiple cell pathways.

Therapeutic Or Clinical Uses

Relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses including eczema, dermatitis, psoriasis, and seborrheic dermatitis.
Temporary relief of minor skin irritations, itching, and rashes from insect bites, poison ivy, poison oak, poison sumac, soaps, detergents, cosmetics, or jewelry.
Management of anogenital pruritus and inflammatory conditions such as hemorrhoids and postirradiation proctitis.
Topical adjunctive treatment of infected dermatoses when combined with anti-infective agents.
Symptomatic relief of oral inflammatory or ulcerative lesions caused by trauma using hydrocortisone acetate paste.
Adjunctive treatment in mild to moderate ulcerative colitis limited to the rectosigmoid or left colon via rectal retention enema.
Rectal foam and suppository formulations for treatment of ulcerative proctitis and other anorectal inflammatory disorders.
General anti-inflammatory therapy preferred over systemic corticosteroids for localized skin conditions to limit systemic absorption.
Temporary relief of minor scalp irritation and itching due to scalp dermatitis using lotions, gels, or foams.
Treatment of localized neurodermatitis and late-phase allergic contact dermatitis.
Symptomatic management of inflammatory phases of xerosis (dry skin).
Prevention of relapse in corticosteroid-responsive dermatoses through maintenance dosing under clinician supervision.
Topical therapy tailored to lesion location and severity for optimal safety and efficacy.

Side Or Adverse Effects

Local irritation including burning, stinging, itching, and erythema at the application site.
Dryness or peeling of the skin due to corticosteroid-induced skin barrier changes.
Folliculitis and acneiform eruptions resulting from prolonged or occluded application.
Hypopigmentation or skin discoloration, especially with long-term use.
Perioral dermatitis and allergic contact dermatitis manifesting as failure to heal or worsening skin condition.
Secondary infections due to local immunosuppression, including bacterial, fungal, or viral overgrowth.
Atrophy of the epidermis and subcutaneous tissue, particularly in intertriginous and facial areas after prolonged use.
Striae (stretch marks) formation with chronic or occlusive dressing use.
Hypertrichosis (excess hair growth) observed in certain cases of chronic application.
Potential systemic effects such as hypothalamic-pituitary-adrenal axis suppression with extensive or prolonged use.
Cushingoid features possible when systemic absorption occurs, especially in children or with occlusive dressings.
Intracranial hypertension reported in pediatric patients with chronic use, presenting with headaches and papilledema.
Delayed wound healing due to corticosteroid effects on fibroblast activity.
Irritation aggravated by occlusive dressings if used improperly on weeping or infected lesions.
Potential for allergic sensitization to excipients or combination products.

Precautions

Avoid application to eyes or mucous membranes unless specifically indicated (e.g., oral paste).
Use lowest effective potency and duration to minimize systemic absorption and adverse effects.
Monitor for hypothalamic-pituitary-adrenal axis suppression in patients using large surface areas or occlusive dressings.
Discontinue use if local skin irritation or allergic contact dermatitis develops; confirm by patch testing if necessary.
Avoid occlusive dressings unless recommended by a clinician to prevent increased absorption and side effects.
Use cautiously in children, especially under 2 years; avoid tight diapers or plastic pants that can act as occlusive dressings.
Evaluate for secondary infections; discontinue corticosteroid if infection worsens.
Avoid use in patients with known hypersensitivity to hydrocortisone or any formulation components.
Exercise caution in patients with severe ulcerative colorectal disease due to risk of intestinal perforation with rectal forms.
Inform patients about proper application techniques and the importance of adherence to prescribed duration and dosing.
Consider potential interactions with other corticosteroid-containing therapies to prevent cumulative systemic effects.
Use caution during pregnancy and lactation; only when benefits justify potential risks.
Avoid chronic continuous use; implement tapering strategies to prevent rebound or adrenal insufficiency.
Be aware that hydrocortisone combinations with anesthetics or antimicrobials warrant attention to respective cautions.
Patients should report any systemic symptoms suggestive of corticosteroid excess such as weight gain, hyperglycemia, or mood changes.

Warnings

Potential for hypothalamic-pituitary-adrenal (HPA) axis suppression, particularly with extensive use, high potency formulations, occlusive dressings, or pediatric use.
Systemic corticosteroid effects including Cushing’s syndrome, hyperglycemia, and glucosuria may occur despite topical administration under certain conditions.
Allergic contact dermatitis may mimic worsening dermatoses; failure to heal should prompt discontinuation and evaluation.
Occlusive dressings significantly increase systemic absorption; prolonged use under occlusion increases risk of systemic and local adverse effects.
Do not use on infected skin unless appropriate anti-infective therapy is concurrently administered; corticosteroids may mask signs of infection or delay healing.
Use rectal forms cautiously in patients with intestinal obstruction, abscesses, peritonitis, fistulas, or recent intestinal surgery due to risk of perforation.
Do not use occlusive dressings on weeping or exudative lesions as this may enhance systemic absorption and secondary infection risk.
Close monitoring recommended in pediatric patients due to increased susceptibility to systemic effects and growth suppression.
Avoid inadvertent ingestion for oral paste formulations; intended for topical mucosal application only.
Discontinue if no improvement is observed within recommended treatment durations to reassess diagnosis.
Patients should be monitored for signs of corticosteroid insufficiency during and after withdrawal of treatment, especially in children.
Use with caution in patients with tuberculosis of the skin, fungal, viral infections, and vaccinia due to immunosuppressive properties.
Avoid use near the eyes to prevent glaucoma and cataract formation associated with corticosteroid exposure.
Remove occlusive dressings if patient develops fever or signs of systemic toxicity to reduce absorption.
Patients should be educated on the importance of not exceeding prescribed frequency or duration to reduce risks.

Contraindication

Known hypersensitivity or allergy to hydrocortisone or any component of the formulation.
Rectal corticosteroid therapy contraindicated in patients with intestinal obstruction, abscess, impending perforation, or peritonitis.
Use is contraindicated in patients with extensive fistulas, fresh intestinal anastomoses, or sinus tracts when administering rectally.
Avoid topical use on untreated bacterial, fungal, or viral skin infections unless appropriate antimicrobial therapy is concurrently used.
Do not use occlusive dressings on primary skin infections or open weeping lesions.
Contraindicated in individuals with hypersensitivity to corticosteroids in combination products containing hydrocortisone.
Avoid use in patients with systemic fungal infections when systemic absorption is a concern.
Contraindicated in cases with known steroid-induced rosacea or perioral dermatitis.
Use contraindicated in children under 2 years of age without clinician supervision for nonprescription formulations.
Avoid usage in patients with severe ulcerative colorectal disease for rectal formulations without full proctologic assessment.
Do not apply to eyes or periocular areas to avoid corticosteroid-related ocular complications.
Avoid use in patients with conditions that may be exacerbated by corticosteroid-induced immunosuppression.

Drug Interactions

Potential pharmacologic interactions with other corticosteroid-containing preparations increase risk of systemic corticosteroid effects.
Concurrent use with immunosuppressive or anti-inflammatory agents may potentiate therapeutic effects or adverse effects.
Use with caution alongside topical anti-infectives (e.g., neomycin, polymyxin B) as corticosteroids may mask infection signs or alter test results.
Steroids can potentially result in false-negative nitroblue-tetrazolium tests for bacterial infections.
Concurrent systemic corticosteroid therapy may increase cumulative systemic exposure and related adverse effects.
Combination with agents that impair skin barrier function may augment systemic absorption.
Co-administration with drugs influencing hepatic metabolism (e.g., CYP3A4 inhibitors) could alter corticosteroid metabolism if systemically absorbed.
Avoid unmonitored use with other potent topical steroids to prevent additive suppression of HPA axis.
Interactions with diabetic medications may necessitate glucose monitoring due to corticosteroid-induced hyperglycemia.
Concurrent use of topical corticosteroids with skin irritants or sensitizers may exacerbate local adverse effects.
Interaction with vaccines is possible due to immunosuppressive effects; live vaccines should be avoided if systemic absorption is significant.
Use with diuretics could theoretically enhance hypokalemic effects of systemic corticosteroids.
Topical corticosteroids may reduce the efficacy of skin tests used for diagnosing allergies or infections.
Concurrent use with anticoagulants requires caution as corticosteroids may alter coagulation parameters.
Interactions with hormonal contraceptives or other hormonal agents have not been documented but consider systemic corticosteroid effects.

Preparations Of The Drug

Topical creams containing hydrocortisone in concentrations ranging from 0.5% to 2.5% with various proprietary brand formulations incorporating aloe, parabens, propylene glycol, and other excipients.
Lotions and gels formulated for application on hairy or sensitive areas, including scalp dermatitis.
Ointments providing occlusive properties for dry, scaly lesions.
Solutions and sprays with alcohol-based vehicles designed for better penetration and ease of use on scalp and other hairy areas.
Paste formulations (e.g., hydrocortisone acetate paste) for oral mucosal application in ulcerative lesions.
Rectal formulations including creams, foams (aerosol foam suspensions), suspensions (retention enemas), and suppositories available in 1%, 10%, 25 mg, and 30 mg doses for inflammatory colorectal conditions.
Combination products containing hydrocortisone with antimicrobial agents such as bacitracin, neomycin, and polymyxin B for enhanced treatment of infected dermatoses (e.g., Cortisporin ointment).
Preparations combining hydrocortisone acetate with local anesthetics such as pramoxine hydrochloride for symptomatic relief in anorectal disorders (e.g., Epifoam, Analpram-HC).
Fixed combination topical creams with antihistamines, astringents, or keratolytics exist but their clinical efficacy varies and caution with concomitant agents is advised.
Medicated soft cloth towelettes (pledgets) saturated with hydrocortisone solution for ease of application and controlled dosing.
Produced by numerous manufacturers globally, hydrocortisone topical products are available in branded and generic forms to facilitate accessibility.
Storage conditions generally involve room temperature in tightly closed containers away from moisture and heat; specific product labeling should be consulted.
Excipients in these formulations can include preservatives, emollients, stabilizers, and other compounds that may influence tolerability and patient preference.
Aerosol foams utilize propellants such as chlorofluorohydrocarbon or hydrocarbon compounds to deliver medication to targeted sites efficiently.